ESSENCE trial: Semaglutide 2.4mg demonstrates statistically significant and superior improvements with in people with MASH
Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD
Helix model can predict 12-month weight loss response of semaglutide in diverse populations
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
STEP 9: Semaglutide reduces knee osteoarthritis-related pain in people with obesity
Semaglutide has positive effect in chronic kidney disease
Semaglutide improves skin condition hidradenitis suppurative in people living with obesity
Journal watch 18/09/2024
Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications
Semaglutide cardiovascular benefits are maintained in people with impaired kidney function
